Search
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[A249945] Birch bark extract is obtained from the white part of the birch tree bark, and the main species of trees used for production are _Betula pendula_ Roth (silver birch) and _Betula pubescens_ Ehrh … [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsChlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxiko...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDigitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPicrotoxin
go.drugbank.com/drugs/DB00466ExperimentalAlthough it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Categories: GABA-A Receptor AntagonistsAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnIt was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. It has been canceled and withdrawn from the market since August 12, 1997.[L1113]
Veru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
Categories: Experimental Unapproved Treatments for COVID-19Pirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnAn antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)